myPlatelet test is a India’s first combination test comprising genetic profiling for the presence of common variants of CYP2C19 gene that affect the bioavailability of clopidogrel (, and a platelet function test for evaluating platelet reactivity in PCI-stent patients.  It is highly specific and sensitive compared to the commonly used Light Transmission Aggregometry (LTA), and correlates well with the plasma levels of anti-platelet medication. It is able to detect high risk of thrombosis or blood clotting, as well as excessive bleeding. The value of this assay in preventing post-procedural major adverse cardiac events or MACE in patients who underwent PCI has been demonstrated in several studies world-wide summarized in the paper (